Exposure of Vioxx “Ghostwriting” Another Example of How Litigation Can Benefit Society (and Why Big Business/Pharma Fears It)

Product liability litigation involving rofecoxib (Vioxx) has led to the disclosure of materials that has provided direct evidence of something that has long been suspected but well-hidden by industry; the manipulation of pharmaceutical studies by for-profit manufacturers of pharmaceuticals and medical devices of study results, using authors, editors, and reviewers to misrepresent research data and manipulate clinical research articles and clinical reviews.

Reports published in the Journal of the American Medical Association (JAMA) based upon a review of materials disclosed by Merck & Co. in the course of the Vioxx litigation claim Merck & Co. frequently paid academic … Read the rest

New York City and New York State File Suit Against MERCK Alleging Medicaid Fraud

Both New York City and New York State have joined together and, following the example of various other states, including Louisiana Mississippi and Utah, have filed suit against Merck& Company.

It is alleged that Merck not only defrauded consumers but also defrauded the state Medicaid program and other government insurance programs by purposefully concealing the dangerous side effects of Vioxx.

Vioxx was prescribed to patients for the treatment of migraines and arthritis but caused a high increase in heart attacks and strokes, and was pulled off the market in September of 2004.

Medicaid claims that had Merck been forthcoming of … Read the rest